Fadi W. Abdul‐Karim
YOU?
Author Swipe
View article: S1 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S1 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 1
View article: S1 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S1 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 1 Legend
View article: S4 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S4 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 4 Legend
View article: S8 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S8 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 8 Legend
View article: S3 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S3 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 3 Legend
View article: S5 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S5 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 5 Legend
View article: S4 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S4 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 4
View article: S2 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S2 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 2
View article: S6 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S6 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 6
View article: S7 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S7 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 7
View article: S3 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S3 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 3
View article: S7 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S7 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 7 Legend
View article: S6 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S6 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 6 Legend
View article: S2 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S2 Legend from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 2 Legend
View article: S5 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis
S5 from TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis Open
Supplemental Figure 5
View article: Knowledge of female and male university students in Lebanon about female breast cancer: A quantitative study
Knowledge of female and male university students in Lebanon about female breast cancer: A quantitative study Open
College students play a vital role in fostering awareness and support for female breast cancer initiatives. This study assessed the knowledge of breast cancer among female and male university students at the University of Balamand through …
View article: Materials and Methods from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Materials and Methods from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Supplementary Materials and Methods.
View article: Figure S6 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Figure S6 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Figure S6 shows blots of total protein staining from Figure 4, quantitation of EGFR following YES1 silencing from individual siRNAs, and time course of YES1 silencing probing for EGFR protein and mRNA in non-small cell lung cancer cells.
View article: Figure S7 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Figure S7 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Figure S7 shows synergy analysis of YES1 and EGFR inhibitors, YES1 inhibitor efficacy in PC-9 cells, and percentage of apoptotic or proliferating cells as single agents or in combination of YES1 and EGFR inhibitors.
View article: Figure S2 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Figure S2 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Figure S2 shows blots of total protein staining from Figure 2, quantitation of EGFR following YES1 silencing from individual siRNAS, and quantitation of phosphorylated EGFR following YES1 silencing.
View article: Table S2 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Table S2 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Table S2 shows the primary antibodies used for western blot analysis.
View article: Table S1 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Table S1 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Table S1 shows the products used in silencing and overexpression of genes or proteins of interest.
View article: Figure S3 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Figure S3 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Figure S3 shows correlation analysis of FYN and SRC mRNA expressions to EGFR protein, blots and quantitation of HER2 and HER3 following YES1 silencing, and correlation analysis of YES1 mRNA expression to HER2 or HER3 protein.
View article: Figure S8 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Figure S8 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Figure S8 shows mouse weight of YES1 and EGFR inhibitor treatments shown in Figure 6.
View article: Data from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Data from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
EGFR is a highly expressed driver of many cancers, yet the utility of EGFR inhibitors (EGFRi) is limited to cancers that harbor sensitizing mutations in the EGFR gene because of dose-limiting toxicities. Rather than conventionally b…
View article: Figure S4 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Figure S4 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Figure S4 shows time course of YES1 silencing probing for EGFR protein and mRNA, HER2 and HER3 expression following YES1 silencing, and western blots with quantitation of Jun and Fos family members following YES1 silencing.
View article: Figure S1 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Figure S1 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Figure S1 shows blot of total protein staining from Figure 1 and quantitation of proliferating cells following YES1 silencing.
View article: Table S3 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Table S3 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Table S3 shows the linear expression of the proteins assessed in the RPPA following YES1 silencing.
View article: Figure S5 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Figure S5 from Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open
Figure S5 shows blots of total protein staining from Figure 3 and blots with quantitation of phosphorylated STAT3, ERK, AKT, and p38 following YES1 silencing.
View article: Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors
Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors Open